

FOR PROFESSIONAL USE ONLY**Rx Only**

For use on Access 2, DxC 500i, UniCel DxC 600i, UniCel Dxl 600, UniCel Dxl 800, UniCel DxC 880i, UniCel DxC 860i, UniCel DxC 680i, and UniCel DxC 660i systems

PRINCIPLE**INTENDED USE**

The Access Ferritin assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of ferritin levels in human serum and plasma (heparin) using the Access Immunoassay Systems.

SUMMARY AND EXPLANATION

Ferritin is used as an aid in the diagnosis of iron deficiency or iron overload.^{1,2}

Ferritin is a large spherical protein consisting of 24 non-covalently linked subunits and having a molecular weight of approximately 450,000.³ The subunits form a shell surrounding a central core containing variable amounts of ferric hydroxyphosphate.⁴ One molecule of ferritin is capable of binding between 4,000 and 5,000 atoms of iron, making ferritin a major iron storage protein in tissues.⁵

Found chiefly in the cytoplasm of cells of the reticuloendothelial system, it once was thought that ferritin did not appear in plasma or extracellular fluid under normal conditions. However, the development of a sensitive immunoradiometric technique by Addison, et al., in 1972, resulted in the discovery that ferritin is a constituent of all normal human serum.⁶ Through this and other work, it was determined that the concentration of ferritin was directly proportional to the total iron stores in the body, resulting in serum ferritin levels becoming a common diagnostic tool in the evaluation of iron status.²

In most normal adults serum ferritin levels ranges from 10-300 ng/mL ($\mu\text{g/L}$), but concentrations vary with age and sex.^{2,3} There is a sharp rise in serum ferritin levels in the first month of life, coinciding with the depression of bone marrow erythropoiesis.³ Within two or three months, erythropoiesis becomes reactivated and there is a drop in the concentration of serum ferritin. By six months, the concentration is reduced to fairly low levels where they remain throughout childhood. There is no sex difference until the onset of puberty, at which time ferritin levels rise, particularly in males.³ There is a significant positive correlation between age and serum ferritin levels in females, but not in males.⁷

Addison, et al., found that patients with iron deficiency anemia have serum ferritin levels approximately one tenth of normal subjects, while patients with iron overload (hemochromatosis, hemosiderosis) have serum ferritin levels much higher than normal.⁶ Other studies also suggest that serum ferritin levels provide a sensitive means of detecting iron deficiency at an early stage.^{4,7,8} In addition, serum ferritin is widely recognized as an acute phase reactant and marker of acute and chronic inflammation, and is nonspecifically elevated in a wide range of inflammatory conditions.²

Traditionally, the estimation of stainable iron in bone marrow biopsies was the accepted method for the evaluation of body iron stores. However, this method is traumatic for the patient and only semi-quantitative. Other methods, such as serum iron determination, total iron binding capacity (TIBC) and percent saturation of transferrin are subject to diurnal variations and are often imprecise. These latter methods also do not discriminate between depleted iron stores and conditions associated with defective iron release (eg. anemia of chronic disease).⁹ The Access Ferritin assay is based

on the two-site immunoradiometric assay (IRMA) described by Addison, et al., but utilizes an enzyme labeled antibody in place of the radiolabeled tracer.⁶ The measurement of ferritin is very well suited to this assay method as its very large size easily permits the simultaneous binding of the required two (or more) antibodies.

METHODOLOGY

The Access Ferritin assay is a two-site immunoenzymatic (“sandwich”) assay. A sample is added to a reaction vessel with goat anti-ferritin-alkaline phosphatase conjugate, and paramagnetic particles coated with goat anti-mouse: mouse anti-ferritin complexes. Serum or plasma (heparin) ferritin binds to the immobilized monoclonal anti-ferritin on the solid phase, while the goat anti-ferritin enzyme conjugate reacts with different antigenic sites on the ferritin molecules.

After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Then, the chemiluminescent substrate is added to the vessel and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of ferritin in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve.

SPECIMEN

SPECIMEN COLLECTION AND PREPARATION

1. Serum and plasma (heparin) are the recommended samples.
2. Observe the following recommendations for handling, processing, and storing blood samples:¹⁰
 - Collect all blood samples observing routine precautions for venipuncture.
 - Allow serum samples to clot completely before centrifugation.
 - Keep tubes stoppered at all times.
 - Physically separate serum or plasma from contact with cells as soon as possible.
 - Store samples tightly stoppered at room temperature (15 to 30°C) for no longer than 8 hours.
 - If the assay will not be completed within eight hours, refrigerate the samples at 2 to 8°C.
 - If the assay will not be completed within 48 hours, or for shipment of samples, freeze at -20°C or colder.
 - Thaw samples only once.
3. Use the following guidelines when preparing specimens:
 - Ensure residual fibrin and cellular matter has been removed prior to analysis.
 - Follow blood collection tube manufacturer's recommendations for centrifugation.
4. Each laboratory should determine the acceptability of its own blood collection tubes and serum separation products. Variations in these products may exist between manufacturers and, at times, from lot-to-lot.
5. Avoid assaying grossly hemolyzed samples in that ferritin can be released from lysed red cells.

REAGENTS

PRODUCT INFORMATION

Access Ferritin Reagent Pack

Cat. No. 33020: 100 determinations, 2 packs, 50 tests/pack

- Provided ready to use.
- Store upright and refrigerate at 2 to 10°C.
- Refrigerate at 2 to 10°C for a minimum of 2 hours before use on the instrument.

- Stable until the expiration date stated on the label when stored at 2 to 10°C.
- Stable at 2 to 10°C for 28 days after initial use.
- Signs of possible deterioration are a broken elastomeric layer on the pack or control values out of range.
- If the reagent pack is damaged (i.e., broken elastomer), discard the pack.
- All antisera are polyclonal unless otherwise indicated.


Well	Contents	Ingredients
R1a:	3.22 mL	Paramagnetic particles coated with goat anti mouse IgG: mouse monoclonal anti-ferritin complexes suspended in TRIS buffered saline, with surfactant, bovine serum albumin (BSA), < 0.1% sodium azide, and 0.1% ProClin* 300.
R1b:	2.98 mL	Goat anti-ferritin-alkaline phosphatase (bovine) conjugate in TRIS buffered saline, with surfactant, BSA, protein (goat, mouse), < 0.1% sodium azide, and 0.1% ProClin 300.

*ProClin is a trademark of LANXESS Corp.

WARNING AND PRECAUTIONS

- For *in vitro* diagnostic use.
- Patient samples and blood-derived products may be routinely processed with minimum risk using the procedure described. However, handle these products as potentially infectious according to universal precautions and good clinical laboratory practices, regardless of their origin, treatment, or prior certification. Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers in accordance with local regulations and guidelines.
- For hazards presented by the product refer to the following sections: REACTIVE INGREDIENTS and GHS HAZARD CLASSIFICATION.

REACTIVE INGREDIENTS

 CAUTION
<p>Sodium azide preservative may form explosive compounds in metal drain lines. See NIOSH Bulletin: Explosive Azide Hazard (8/16/76). To avoid the possible build-up of azide compounds, flush wastepipes with water after the disposal of undiluted reagent. Sodium azide disposal must be in accordance with appropriate local regulations.</p>

GHS HAZARD CLASSIFICATION

Ferritin Particles
(Compartment R1a)

WARNING



H317	May cause an allergic skin reaction.
H412	Harmful to aquatic life with long lasting effects.
P273	Avoid release to the environment.
P280	Wear protective gloves, protective clothing and eye/face protection.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

Ferritin Conjugate
(Compartment R1b)

WARNING



H317	May cause an allergic skin reaction.
H412	Harmful to aquatic life with long lasting effects.
P273	Avoid release to the environment.
P280	Wear protective gloves, protective clothing and eye/face protection.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

	Safety Data Sheet is available at beckmancoulter.com/techdocs
--	---

MATERIALS NEEDED BUT NOT SUPPLIED WITH REAGENT KIT

1. Access Ferritin Calibrators
Provided at zero and approximately 10, 50, 200, 500 and 1,500 ng/mL (µg/L).
Cat. No. 33025
2. Quality Control (QC) materials: commercial control material.
3. Access Sample Diluent A
Cat. No. 81908

4. Access Substrate
Cat. No. 81906
5. Access Wash Buffer II, Cat. No. A16792
UniCel DxI Wash Buffer II, Cat. No. A16793
UniCel DxI Access Immunoassay Systems Wash Buffer II, Cat. No A79784
(Diluent pack for use with the UniCel DxI system onboard dilution feature.)

EQUIPMENT AND MATERIALS

R1 Access Ferritin Reagent Packs

CALIBRATION

CALIBRATION INFORMATION

An active calibration curve is required for all tests. For the Access Ferritin assay, calibration is required every 28 days. Refer to the appropriate system manuals and/or Help system for information on calibration theory, configuring calibrators, calibrator test request entry, and reviewing calibration data.

QUALITY CONTROL

Quality control materials simulate the characteristics of patient samples and are essential for monitoring the system performance of immunochemical assays. Because samples can be processed at any time in a “random access” format rather than a “batch” format, quality control materials should be included in each 24-hour time period.¹¹ Include commercially available quality control materials that cover at least two levels of analyte. More frequent use of controls or the use of additional controls is left to the discretion of the user based on good laboratory practices or laboratory accreditation requirements and applicable laws. Follow manufacturer's instructions for reconstitution and storage. Each laboratory should establish mean values and acceptable ranges to assure proper performance. Quality control results that do not fall within acceptable ranges may indicate invalid test results. Examine all test results generated since obtaining the last acceptable quality control test point for this analyte. Refer to the appropriate system manuals and/or Help system for information about reviewing quality control results.

TESTING PROCEDURE(S)

PROCEDURAL COMMENTS

1. Refer to the appropriate system manuals and/or Help system for a specific description of installation, start-up, principles of operation, system performance characteristics, operating instructions, calibration procedures, operational limitations and precautions, hazards, maintenance, and troubleshooting.
2. Mix contents of new (unpunctured) reagent packs by gently inverting pack several times before loading on the instrument. Do not invert open (punctured) packs.
3. Use ten (10) μ L of sample for each determination in addition to the sample container and system dead volumes. Use sixty-six (66) μ L of sample in addition to the sample container and system dead volumes for each determination run with the DxI system onboard dilution feature. Refer to the appropriate system manuals and/or Help system for the minimum sample volume required.
4. The system default unit of measure for sample results is ng/mL. To change sample reporting units to the International System of Units (SI units), μ g/L, refer to the appropriate system manuals and/or Help system. To manually convert concentrations to the International System, multiply ng/mL by multiplication factor 1.

PROCEDURE

Refer to the appropriate system manuals and/or Help system for information on managing samples, configuring tests, requesting tests, and reviewing test results.

For assaying samples containing < 1,500 ng/mL ($\mu\text{g/L}$) ferritin, select **Ferritin** as the test name. Select **Dil-Fer** as the test name for assaying samples containing > 1,500 ng/mL. Alternatively, Dxl users may use the Dxl onboard dilution feature by selecting **d-Fer** as the test name for assaying samples containing > 1,500 ng/mL. The same reagent pack and calibration curve is used for all assays.

RESULTS INTERPRETATION

Patient test results are determined automatically by the system software. The amount of analyte in the sample is determined from the measured light production by means of the stored calibration data. Patient test results can be reviewed using the appropriate screen. Refer to the appropriate system manuals and/or Help system for complete instructions on reviewing sample results.

REPORTING RESULTS

EXPECTED RESULTS

1. Each laboratory should establish its own reference ranges to assure proper representation of specific populations.
2. Ferritin concentrations were measured in 113 serum samples from apparently healthy male and female subjects using the Access Ferritin assay. The results were as follows:

	n	Geometric Mean (ng/mL, $\mu\text{g/L}$)	95% Range [†] (ng/mL, $\mu\text{g/L}$)
Males	49	105.6	23.9-336.2
Females	64	51.4	11.0-306.8

[†] Non-parametric estimate of 95% confidence interval.

3. Interpret the results of this test in conjunction with the patient's clinical presentation.

PROCEDURAL NOTES

LIMITATIONS

1. Samples can be accurately measured within the analytic range of the lower limit of detection and the highest calibrator value (approximately 0.2-1,500 ng/mL [$\mu\text{g/L}$]). The analytic range for the **Dil-Fer** assay is 1,300 up to approximately 15,000 ng/mL.
 - If a sample contains less than the lower limit of detection for the assay, report the results as less than that value (i.e., < 0.2 ng/mL [$\mu\text{g/L}$]). When the Dxl system onboard dilution feature is used, the system will report results as less than 1,275 ng/mL.
2. To accurately measure samples containing approximately 1,500-15,000 ng/mL, select the **Dil-Fer** test. This test uses the **Ferritin** pack. When **Dil-Fer** is requested, the system autodilutes the sample and reads the resulting dose off the **Ferritin** calibration curve. The system multiplies by the dilution factor defined in the software to calculate final test results. Any neat sample reading < 1,300 ng/mL in the **Dil-Fer** assay should be retested in the **Ferritin** assay. Samples > 1,500 ng/mL in the **Ferritin** assay can be run in the **Dil-Fer** assay or may be assayed with the manual dilution option below.
3. For UniCel Dxl systems:

Samples containing > 1,500 ng/mL can be processed using the Dxl onboard dilution feature. The Dxl system onboard dilution feature automates the dilution process, using one volume of sample with four volumes of UniCel Dxl Access Immunoassay Systems Wash Buffer II, allowing samples to be quantitated up to 7,500 ng/mL. The system reports the results adjusted for the dilution.

4. Manual dilution for samples containing > 1,500 ng/mL for **Ferritin** assay or > 15,000 ng/mL for **Dil-Fer** assay:
 - For **Ferritin** values > 1,500 ng/mL, dilute as follows:
Dilute one volume of sample with four volumes of Access Ferritin Calibrator S0 (zero), Access Sample Diluent A or Access Wash Buffer II. The pre-dilution factor is 5. Run the dilution with the **Ferritin** or **Dil-Fer** assay. (**Note: a manual pre-diluted sample in the Dil-Fer assay may report a < 1,300 ng/mL result.**)
 - For **Dil-Fer** assay values > 15,000 ng/mL, dilute as follows:
For serum samples, dilute one volume of sample with four volumes of Access Ferritin Calibrator S0 (zero), Access Sample Diluent A or Access Wash Buffer II. The pre-dilution factor is 5. Run the dilution with the **Dil-Fer** assay.
 - Type in the pre-dilution factor when entering the test request. Order the **Ferritin** or **Dil-Fer** test. The system will automatically multiply the result by the pre-dilution factor and report that value.
 - If the pre-dilution factor is not used when entering the request, multiply the calculated value by the pre-dilution factor after assaying the diluted sample using the Access **Ferritin** assay or the **Dil-Fer** assay.
 - If the system reports a pre-diluted **Ferritin** result as < 0.2 ng/mL or a pre-diluted **Dil-Fer** result < 1,300 ng/mL, then re-dilute with a lesser dilution.
 - Refer to the appropriate system manuals and/or Help system for additional instructions on processing pre-diluted samples.
5. For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the patient sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays. Additionally, other heterophile antibodies such as human anti-sheep antibodies may be present in patient samples.^{12,13} Such interfering antibodies may cause erroneous results. Carefully evaluate the results of patients suspected of having these antibodies.
6. The Access Ferritin results should be interpreted in light of the total clinical presentation of the patient, including: symptoms, clinical history, data from additional tests and other appropriate information.
7. The Access Ferritin assay does not demonstrate any "hook" effect up to 40,000 ng/mL (µg/L). Extremely high quantities of ferritin may cause a "hook" effect.

PERFORMANCE CHARACTERISTICS

METHODS COMPARISON

A comparison of 153 values using the Access Ferritin assay on the Access Immunoassay System and a commercially available enzyme immunoassay kit gave the following statistical data:

n	Range of Observations (ng/mL)	Intercept (ng/mL)	Slope	Correlation Coefficient (r)
153	2.2-1,313.0	-5.11	1.01	0.993

Comparison of values obtained by assaying clinical samples of serum or plasma (heparin) using the Access Ferritin assay kit gave the following statistical data:

n	Range of Observations (ng/mL)	Intercept (ng/mL)	Slope	Correlation Coefficient (r)
48	6.00-504.64	-2.83	1.05	0.999

DILUTION RECOVERY (LINEARITY)

Gravimetric dilution of two samples containing various ferritin levels with Access Ferritin Calibrator S0 (zero) resulted in the following data:

Sample 1	Expected Concentration (ng/mL)	Determined Concentration (ng/mL)	Recovery (%)
Neat	N/A	949.6	N/A
1/1.98	479.6	465.0	97.0
1/4.33	219.3	216.4	98.7
1/10.80	87.9	88.2	100.3
1/21.98	43.2	43.3	100.2
1/39.32	24.2	24.9	102.9
Mean % Recovery			99.8

Sample 2	Expected Concentration (ng/mL)	Determined Concentration (ng/mL)	Recovery (%)
Neat	N/A	559.3	N/A
1/1.99	281.1	291.4	103.7
1/3.13	178.7	184.1	103.0
1/5.12	109.2	117.3	107.4
1/10.24	54.6	59.6	109.2
1/31.66	17.7	18.0	101.7
Mean % Recovery			105.0

IMPRECISION

The **Ferritin** assay exhibits total imprecision of less than 10% across the assay range. One study, using commercially available human serum based control material generating 20 assays, two replicates per assay, over 20 days provided the following data, analyzed via analysis of variance (ANOVA):^{14,15}

Sample	Grand Mean (n=40) (ng/mL)	Within Run (%CV)	Total Imprecision (%CV)
Low	37.2	2.6	4.1
Medium	118.9	3.6	4.3
High	311.8	3.9	6.3

The **Dil-Fer** assay exhibits total imprecision of less than 20% across the range of the **Dil-Fer** assay.

ANALYTICAL SPECIFICITY / INTERFERENCES

Samples containing up to 5 mg/dL (86 µmol/L) bilirubin, lipemic samples containing the equivalent of 900 mg/dL (10.16 mmol/L) triglycerides, and hemolyzed samples containing up to 300 mg/dL (3 g/L) hemoglobin do not affect the concentration of ferritin assayed. Grossly hemolyzed samples should not be used in that ferritin can be released from lysed red cells.

Samples containing 5-9 g/dL (50-90 g/L) albumin do not affect the concentration of ferritin assayed.

The antibodies used in this kit were raised against liver ferritin. Reactivity to spleen ferritin, as demonstrated by spiking recovery in a serum sample, is equivalent to that of liver ferritin.

ANALYTICAL SENSITIVITY

The lowest detectable level of ferritin distinguishable from zero (Access Ferritin Calibrator S0) with 95% confidence is 0.2 ng/mL (µg/L). This value is determined by processing a complete six-point calibration curve, controls, and ten replicates of the zero calibrator in multiple assays. The analytical sensitivity value is interpolated from the curve at the point that is two standard deviations from the mean measured zero calibrator signal.

ADDITIONAL INFORMATION

For a patient/user/third party in the European Union and in countries with identical regulatory regime (Regulation 2017/746/EU on In vitro Diagnostic Medical Devices); if, during the use of this device or as a result of its use, a serious incident has occurred, please report it to the manufacturer and/or its authorized representative and to your national authority.

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

May be covered by one or more pat. -see www.beckmancoulter.com/patents.

REVISION HISTORY

Revision A

New release of IVDR compliant IFU.

Revision B

Added Translations.

Revision C

Added Translations.

Revision D

Updated ProClin trademark statement.

Revision E

Updated Translations.

Revision F

Updated "For Use" section.


SYMBOLS KEY

Glossary of Symbols is available at beckmancoulter.com/techdocs (document number C02724).

REFERENCES

1. Lopez, Anthony et al. Iron deficiency anaemia. *The Lancet*, Volume 387, Issue 10021, 907 - 916
2. Wang, Wei et al. Serum Ferritin: Past, Present and Future. *Biochim Biophys Acta*.2010 August; 1800(8): 760–769. doi:10.1016/j.bbagen.2010.03.011
3. Jacobs A. Ferritin: an interim review. In *Current topics in hematology*, 1985; No. 5: 25-62. Alan R. Liss, Inc.
4. Crichton RR. Ferritin: structure, synthesis and function. *New England Journal of Medicine*, 1974; 284(25): 1413-1422.
5. Alfrey CP, et al. Characteristics of ferritin isolated from human marrow, spleen, liver and reticulocytes. *Journal of Laboratory and Clinical Medicine*, 1967; 70: 419-428.
6. Addison GM, et al. An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. *Journal of Clinical Pathology*, 1972; 25: 326-329.
7. Cook JD, et al. Serum ferritin as a measure of iron status in normal subjects. *American Journal of Clinical Nutrition*, 1974; 27: 681-687.
8. Jacobs A, et al. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. *British Medical Journal*, 1972; 4: 206-208.
9. Krause MD, Stolc V. Serum ferritin and bone marrow iron status. *American Journal of Clinical Pathology*, 1979; 72(5): 817-820.
10. Approved Guideline - Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests, GP44-A4. 2010. Clinical and Laboratory Standards Institute.
11. Cembrowski GS, Carey RN. *Laboratory quality management: QC ⇒ QA*. ASCP Press, Chicago, IL, 1989.
12. Kricka L. Interferences in immunoassays - still a threat. *Clin Chem* 2000; 46: 1037-1038.
13. Bjerner J, et al. Immunometric assay interference: incidence and prevention. *Clin Chem* 2002; 48: 613-621.
14. Wood JM, Gordon DL, Rudinger AN, Brooks MM. Artfactual elevation of thyroid-stimulating hormone. *The American Journal of Medicine*, February 1991, 90: 261-262.
15. Tentative Guideline - User evaluation of precision performance of clinical chemistry devices, EP5-T, 4, N8, 1984. National Committee for Clinical Laboratory Standards.

EC REP Beckman Coulter Ireland Inc., Lismeehan, O'Callaghan's Mills, Co. Clare, Ireland +(353) (0) 65 683 1100

 Beckman Coulter, Inc., 250 S. Kraemer Blvd., Brea, CA 92821 U.S.A.
+(1) 800-854-3633
www.beckmancoulter.com